In prostate cancer, PGC1α activation induces an ERRα-dependent catabolic state to suppress metastasis [23], whereas in breast cancer, it enhances mitochondrial flexibility to promote metastatic dissemination [21]. Here, PPARGC1A is linked to prostate carcinoma.